NCT02811354 - Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

February 24, 2019

Study Completion Date

February 24, 2020

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

AZD9291

oral administration as a single daily dose of 80 mg

Trial Locations (8)

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Ramathibodi Hospital, Bangkok

RECRUITING

National University Hospital, Singapore

RECRUITING

Pamela Youde Nethersole Eastern Hospital, Chai Wan

RECRUITING

Prince of Wales Hospital, Shatin

RECRUITING

Samsung Medical Center Sungkyunkwan University, Irwon-dong

RECRUITING

Yonsei Cancer Center, Sinchon-dong

RECRUITING

Seoul National University College of Medicine, Yeongeon-dong